AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03617510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
Study NCT02017106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser ablation and sequential phlebectomies
Study NCT02694263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
Study NCT02694263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
Study NCT03843073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Urinary Catheter
Description: Patients will use the Connected Catheter to empty the bladder during the course of treatment.
Study NCT01586715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells without expanded
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study NCT01926509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Study NCT01926509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-8892
Study NCT04403685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
Study NCT00663260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once Daily, 104 weeks
Study NCT00663260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, Once Daily, 104 weeks
Study NCT00663260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once Daily, 104 weeks
Study NCT04160598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV infusion
Description: Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
Study NCT04160598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV infusion
Description: Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
Study NCT04160598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal fentanyl
Description: 10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
Study NCT04160598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal fentanyl
Description: 10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
Study NCT00745355 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality Of Life questionnaires
Description: All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
Study NCT00803049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide (HMR1726)
Description: Tablet, oral administration QD.
Study NCT01701609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Study NCT03842150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biliary atresia screen score
Description: The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
Study NCT00660231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene
Description: Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
Study NCT00660231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
Study NCT02624479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: oral administration of thiosulfate
Study NCT01909245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic Human Islet Cells
Description: Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
Study NCT01909245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
Study NCT01909245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrin 17
Description: Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
Study NCT03969030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEBRA model
Description: The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support
Study NCT04103931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Choices for Aortic Stenosis Decision Aid
Description: A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis.
Study NCT01491919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Subjects will be randomized to Low, Medium, or High dose of Lisinopril
Study NCT04637347 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Catheterization approach
Description: In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
Study NCT00522379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
Study NCT00522379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
Study NCT00522379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch applied daily
Study NCT00522379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
Study NCT00522379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
Study NCT03901365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroscience pain education
Description: In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
Study NCT03901365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional patient education
Description: In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
Study NCT03901365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
Study NCT03617510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
Study NCT03901365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
Study NCT01613586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study NCT01613586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03788356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Diaphragmatic breathing exercise
Study NCT04037982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic pancreaticoduodenectomy
Description: During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
Study NCT04037982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreaticoduodenectomy
Description: During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
Study NCT02102269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: actimove sling
Study NCT03064230 — intervention group
Intervention type: OTHER
Intervention: QoL questionnaire SF-12 and and a screening questionnaire
Description: patient were asked to fill questionnaires
Study NCT01649804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks for 104 weeks
Study NCT00901407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
Study NCT00901407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo: 1-2 tablets bid; 10 weeks
Study NCT00901407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
Study NCT00901407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paroxetine
Description: open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
Study NCT02488850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study NCT02488850 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Study NCT03873610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 1
Description: The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
Study NCT03873610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 2
Description: The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
Study NCT00924079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine
Description: oral dosage form, 66 mg, single dose
Study NCT05038046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) daycare model
Description: Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
Study NCT00751218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: desloratadine, 5mg oral tablets, once daily for 28 days
Study NCT00751218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily for 28 days
Study NCT00751218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine
Description: cetirizine, 10 mg capsules once daily for 28 days
Study NCT00778804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
Study NCT04017208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2713
Description: Administered intravenously
Study NCT04017208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered intravenously
Study NCT04347538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Nasal Irrigation
Description: Saline nasal irrigation BID
Study NCT04347538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline with Baby Shampoo Nasal Irrigation
Description: Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
Study NCT01318642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
Study NCT01969578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide + triptorelin
Study NCT01969578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Doxorubicin
Study NCT01969578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin + Paclitaxel
Study NCT03551119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: See previous description
Study NCT03551119 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced usual care
Description: See previous description
Study NCT01318642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
Study NCT01318642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
Study NCT01318642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
Study NCT03408262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvCN54
Description: Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Study NCT03408262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-CN54
Description: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice + Immediate
Description: Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
Study NCT03408262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CN54
Description: Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
Study NCT03408262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Study NCT03408262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140/MPLA
Description: Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
Study NCT01710150 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CTI ablation alone
Study NCT01710150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTI ablation and Pulmonary vein isolation (PVI)
Study NCT02990858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 SC injections
Study NCT00609648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Relaxation Learning
Description: A self-paced computer program for reducing dental injection fear.
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice + Gradual
Description: Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
Study NCT00609648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: A pamphlet reassuring patients about dental injections.
Study NCT01353638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dipeptiven (Alanyl-glutamine-dipeptide)
Description: Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
Study NCT02959151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned + Immediate
Description: Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned + Gradual
Description: Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
Study NCT03749473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily performance feedback
Description: Participants will receive daily performance feedback on their daily step count.